New study checks if popular hair loss drug works outside of clinical trials

This study looks at how well the drug ritlecitinib works for people with severe alopecia areata (a condition causing patchy or total hair loss) in real-world settings, not just in controlled trials. Researchers will review medical records of about 300 patients aged 12 and older who started ritlecitinib between July 2023 and February 2025. The goal is to understand patient backgrounds, treatment patterns, and actual hair regrowth outcomes.